The present study investigated the genoprotective and genotoxic effects of myricetin bulk (10 µM) and nano forms (20 µM) in the lymphocytes from pre-cancerous, monoclonal gammopathy of unknown significance (MGUS) patients and healthy individuals using the Comet and micronucleus assays. The study also evaluated the effect of myricetin on P53 expression levels, using the Western blot technique. Results showed that throughout the in-vitro treatment, lymphocytes from the patients group had higher levels of baseline DNA damage compared to the healthy group. Myricetin in both forms induced significant DNA damage, only at higher concentrations (>40 µM). The micronucleus assay showed a significant reduction (P < 0.01) in the frequency of micronuclei in mono-nucleated cells in the patient group treated with the nano form of myricetin at the non-toxic dose of 20 µM. There was a significant increase in both gene and protein P53 levels in lymphocytes isolated from healthy individuals and pre-cancerous patients. These results suggested a protective effect of myricetin and indicated its nutritional supplement potential for protection against cancer development among patients suffering from MGUS.

中文翻译：

---

对 MGUS 患者和健康个体淋巴细胞中杨梅素本体和纳米形式的保护和遗传毒性作用的体外研究

本研究使用彗星和微核测定法研究了大量杨梅素 (10 µM) 和纳米形式 (20 µM) 对来自癌前、意义不明的单克隆丙种球蛋白病 (MGUS) 患者和健康个体的淋巴细胞的基因保护和基因毒性作用。该研究还使用蛋白质印迹技术评估了杨梅素对 P53 表达水平的影响。结果表明，在整个体外治疗过程中，与健康组相比，患者组的淋巴细胞具有更高的基线 DNA 损伤水平。两种形式的杨梅素都会引起显着的 DNA 损伤，只有在较高浓度 (>40 µM) 时。微核检测显示显着减少（P < 0. 01) 在用无毒剂量 20 µM 的杨梅素纳米形式治疗的患者组中单核细胞中的微核频率。从健康个体和癌前患者分离的淋巴细胞中基因和蛋白质 P53 水平显着增加。这些结果表明杨梅素具有保护作用，并表明其营养补充剂具有预防 MGUS 患者癌症发展的潜力。